We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Product News

Glycotope Enrolls First Patients in Phase I Trial with TrasGEX™

Rectangle Image
Product News

Glycotope Enrolls First Patients in Phase I Trial with TrasGEX™

Glycotope GmbH, has announced the enrollment of the first patients in a phase I dose finding trial to evaluate safety and tolerability of TrasGEX™. TrasGEX™ is a biobetter of the marketed Trastuzumab / Herceptin™ targeting the HER2-receptor, commonly overexpressed in a variety of cancers.

TrasGEX™ has been glycooptimized to yield a manifold higher anti-tumor activity and is supposed to be suitable for the treatment of an enlarged patient spectrum.

It was developed using GlycoExpress™, the company's development and production platform based on glycoengineered human cell lines for biopharmaceuticals with fully human and optimized glycosylation.

"We are delighted to see our 4th glycooptimized biopharmaceutical product in clinical trials", says Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope.

Dr. Goletz continued, "After CetuGEX™ and PankoMab-GEX™, TrasGEX is our 3rd anti-cancer antibody which entered clinical trials in time. GlycoExpress has been proven to be the broadest glycooptimization technology not only for antibodies but also for most other glycoproteins. Our glycooptimized Follicle-Stimulating Hormone FSH-GEX™ has already completed clinical phase Ia with very exciting results. Currently we are advancing a broad range of pre-clinical products in various therapeutic areas".

Advertisement